Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemochromatosis | 17 | 2012 | 70 | 1.510 |
Why?
|
Epilepsy | 5 | 2021 | 50 | 1.470 |
Why?
|
Depression | 6 | 2021 | 361 | 1.250 |
Why?
|
Female | 113 | 2020 | 17679 | 0.960 |
Why?
|
Influenza, Human | 9 | 2016 | 106 | 0.960 |
Why?
|
Iron Overload | 10 | 2012 | 38 | 0.920 |
Why?
|
Humans | 130 | 2022 | 28304 | 0.890 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 7 | 2020 | 27 | 0.880 |
Why?
|
Women's Health | 7 | 2020 | 226 | 0.800 |
Why?
|
Histocompatibility Antigens Class I | 9 | 2010 | 58 | 0.790 |
Why?
|
Male | 94 | 2020 | 16967 | 0.770 |
Why?
|
Adult | 59 | 2021 | 8243 | 0.770 |
Why?
|
Pesticides | 6 | 2016 | 183 | 0.760 |
Why?
|
Infant, Very Low Birth Weight | 7 | 2017 | 48 | 0.750 |
Why?
|
Iron | 10 | 2012 | 114 | 0.740 |
Why?
|
Membrane Proteins | 10 | 2012 | 260 | 0.730 |
Why?
|
Ferritins | 8 | 2010 | 46 | 0.720 |
Why?
|
Mutation | 10 | 2020 | 451 | 0.650 |
Why?
|
Hispanic Americans | 10 | 2016 | 935 | 0.630 |
Why?
|
Diabetes Mellitus, Type 2 | 13 | 2019 | 1556 | 0.620 |
Why?
|
Anxiety | 5 | 2021 | 132 | 0.600 |
Why?
|
Cognition Disorders | 5 | 2019 | 388 | 0.570 |
Why?
|
Middle Aged | 48 | 2020 | 10678 | 0.570 |
Why?
|
Occupational Exposure | 3 | 2016 | 218 | 0.570 |
Why?
|
Dystonic Disorders | 5 | 2020 | 12 | 0.560 |
Why?
|
Genome-Wide Association Study | 10 | 2022 | 615 | 0.550 |
Why?
|
North Carolina | 29 | 2016 | 1412 | 0.550 |
Why?
|
Transients and Migrants | 2 | 2016 | 275 | 0.540 |
Why?
|
Adolescent | 34 | 2018 | 3184 | 0.530 |
Why?
|
Aged | 44 | 2020 | 9256 | 0.520 |
Why?
|
Postural Balance | 1 | 2016 | 109 | 0.500 |
Why?
|
Influenza A Virus, H1N1 Subtype | 5 | 2016 | 43 | 0.500 |
Why?
|
African Americans | 15 | 2016 | 1513 | 0.500 |
Why?
|
Infant, Newborn | 17 | 2017 | 587 | 0.490 |
Why?
|
Quality of Life | 8 | 2019 | 792 | 0.490 |
Why?
|
Mass Screening | 5 | 2021 | 218 | 0.480 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 224 | 0.450 |
Why?
|
Diabetes Mellitus | 9 | 2008 | 366 | 0.450 |
Why?
|
Diabetes Mellitus, Type 1 | 6 | 2010 | 187 | 0.450 |
Why?
|
Continental Population Groups | 6 | 2016 | 229 | 0.420 |
Why?
|
Genetic Predisposition to Disease | 10 | 2019 | 938 | 0.420 |
Why?
|
Rural Population | 10 | 2010 | 244 | 0.410 |
Why?
|
Adrenal Cortex Hormones | 3 | 2017 | 147 | 0.410 |
Why?
|
Dementia | 3 | 2019 | 231 | 0.400 |
Why?
|
Cross-Sectional Studies | 15 | 2021 | 1345 | 0.400 |
Why?
|
European Continental Ancestry Group | 14 | 2016 | 1203 | 0.390 |
Why?
|
Psoriasis | 6 | 2005 | 334 | 0.390 |
Why?
|
Glucocorticoids | 4 | 2003 | 146 | 0.390 |
Why?
|
Dexamethasone | 2 | 2001 | 39 | 0.380 |
Why?
|
Bronchopulmonary Dysplasia | 4 | 2002 | 10 | 0.380 |
Why?
|
Prenatal Exposure Delayed Effects | 3 | 2016 | 82 | 0.380 |
Why?
|
Prospective Studies | 10 | 2021 | 1932 | 0.380 |
Why?
|
Hospitalization | 6 | 2013 | 386 | 0.370 |
Why?
|
Risk Factors | 20 | 2020 | 3520 | 0.370 |
Why?
|
Anxiety Disorders | 3 | 2021 | 57 | 0.340 |
Why?
|
Genetic Testing | 6 | 2009 | 93 | 0.340 |
Why?
|
Child, Preschool | 17 | 2018 | 1126 | 0.340 |
Why?
|
Child | 21 | 2019 | 2151 | 0.330 |
Why?
|
United States | 21 | 2020 | 3588 | 0.330 |
Why?
|
Genotype | 18 | 2014 | 813 | 0.320 |
Why?
|
Blood Pressure | 7 | 2022 | 861 | 0.320 |
Why?
|
Estrogen Replacement Therapy | 3 | 2020 | 183 | 0.310 |
Why?
|
Laser Therapy | 3 | 2002 | 38 | 0.310 |
Why?
|
Asthma | 4 | 2003 | 396 | 0.310 |
Why?
|
Influenza Vaccines | 3 | 2013 | 70 | 0.300 |
Why?
|
Infant | 14 | 2016 | 928 | 0.290 |
Why?
|
Ethnic Groups | 8 | 2016 | 450 | 0.290 |
Why?
|
Phenotype | 12 | 2016 | 653 | 0.290 |
Why?
|
Genome, Human | 3 | 2019 | 148 | 0.290 |
Why?
|
Genetic Variation | 3 | 2019 | 278 | 0.290 |
Why?
|
Self Care | 7 | 2016 | 133 | 0.290 |
Why?
|
Agriculture | 6 | 2008 | 174 | 0.290 |
Why?
|
Population Surveillance | 5 | 2015 | 116 | 0.280 |
Why?
|
Polymorphism, Single Nucleotide | 10 | 2022 | 1236 | 0.280 |
Why?
|
Transferrin | 6 | 2007 | 33 | 0.280 |
Why?
|
Health Behavior | 4 | 2017 | 213 | 0.280 |
Why?
|
Overweight | 2 | 2018 | 254 | 0.270 |
Why?
|
Dietary Fats | 3 | 2009 | 107 | 0.270 |
Why?
|
Environmental Exposure | 4 | 2008 | 86 | 0.260 |
Why?
|
Aged, 80 and over | 17 | 2019 | 3562 | 0.260 |
Why?
|
Disability Evaluation | 2 | 2016 | 202 | 0.260 |
Why?
|
Mothers | 4 | 2014 | 78 | 0.250 |
Why?
|
Survivors | 2 | 2016 | 141 | 0.250 |
Why?
|
Premature Birth | 2 | 2015 | 38 | 0.250 |
Why?
|
Indians, North American | 8 | 2010 | 111 | 0.250 |
Why?
|
Age of Onset | 4 | 2019 | 98 | 0.240 |
Why?
|
Prevalence | 11 | 2019 | 881 | 0.240 |
Why?
|
Diabetes Complications | 4 | 2010 | 184 | 0.240 |
Why?
|
Reproducibility of Results | 5 | 2021 | 700 | 0.240 |
Why?
|
Geriatric Assessment | 2 | 2016 | 328 | 0.240 |
Why?
|
Health Status | 6 | 2019 | 360 | 0.230 |
Why?
|
Ultraviolet Therapy | 3 | 2002 | 39 | 0.230 |
Why?
|
Renin-Angiotensin System | 2 | 2016 | 247 | 0.230 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2021 | 87 | 0.230 |
Why?
|
Pre-Eclampsia | 2 | 2014 | 55 | 0.220 |
Why?
|
Hypertension | 3 | 2022 | 978 | 0.220 |
Why?
|
Activities of Daily Living | 3 | 2015 | 216 | 0.220 |
Why?
|
Homozygote | 5 | 2010 | 61 | 0.220 |
Why?
|
Smoking | 2 | 2017 | 389 | 0.210 |
Why?
|
Young Adult | 10 | 2018 | 2321 | 0.210 |
Why?
|
Obesity | 4 | 2018 | 1079 | 0.200 |
Why?
|
Dystonia | 3 | 2019 | 12 | 0.200 |
Why?
|
Albuminuria | 3 | 2008 | 207 | 0.200 |
Why?
|
Chromosomes, Human, Pair 16 | 2 | 2019 | 15 | 0.200 |
Why?
|
Blood Glucose | 3 | 2014 | 485 | 0.200 |
Why?
|
Birth Weight | 4 | 2017 | 38 | 0.200 |
Why?
|
Retinopathy of Prematurity | 1 | 2001 | 8 | 0.200 |
Why?
|
Psychiatry | 1 | 2020 | 12 | 0.200 |
Why?
|
Dysarthria | 1 | 2020 | 3 | 0.200 |
Why?
|
Biomedical Research | 2 | 2020 | 144 | 0.200 |
Why?
|
Speech | 1 | 2020 | 6 | 0.200 |
Why?
|
Dysphonia | 1 | 2020 | 8 | 0.190 |
Why?
|
Prostaglandin D2 | 1 | 2000 | 4 | 0.190 |
Why?
|
Housing | 3 | 2006 | 59 | 0.190 |
Why?
|
Aging | 3 | 2016 | 857 | 0.190 |
Why?
|
Cohort Studies | 8 | 2018 | 1673 | 0.190 |
Why?
|
Vitamin A | 1 | 2000 | 19 | 0.190 |
Why?
|
Transposition of Great Vessels | 1 | 2000 | 2 | 0.190 |
Why?
|
Ventricular Dysfunction | 1 | 2000 | 4 | 0.190 |
Why?
|
Dinoprostone | 1 | 2000 | 35 | 0.190 |
Why?
|
Neoplasms | 2 | 2016 | 596 | 0.180 |
Why?
|
Respiratory Tract Infections | 2 | 2018 | 40 | 0.180 |
Why?
|
Hemiplegia | 1 | 2019 | 11 | 0.180 |
Why?
|
Milk | 1 | 1999 | 11 | 0.180 |
Why?
|
Polymorphism, Genetic | 2 | 2013 | 211 | 0.180 |
Why?
|
Lactation | 1 | 1999 | 14 | 0.180 |
Why?
|
African Continental Ancestry Group | 6 | 2010 | 376 | 0.180 |
Why?
|
Resilience, Psychological | 1 | 2019 | 15 | 0.180 |
Why?
|
Pregnancy | 7 | 2016 | 799 | 0.180 |
Why?
|
Agricultural Workers' Diseases | 2 | 2006 | 86 | 0.180 |
Why?
|
Patient Participation | 1 | 2020 | 60 | 0.180 |
Why?
|
Apolipoprotein E4 | 1 | 2019 | 58 | 0.180 |
Why?
|
Primary Health Care | 4 | 2005 | 174 | 0.180 |
Why?
|
Body Weight | 2 | 2018 | 289 | 0.170 |
Why?
|
Ataxia | 2 | 2016 | 6 | 0.170 |
Why?
|
Exercise | 2 | 2019 | 567 | 0.170 |
Why?
|
Uric Acid | 2 | 2017 | 24 | 0.170 |
Why?
|
Hormone Replacement Therapy | 1 | 2019 | 88 | 0.170 |
Why?
|
Logistic Models | 6 | 2019 | 727 | 0.170 |
Why?
|
Parkinsonian Disorders | 2 | 2019 | 7 | 0.170 |
Why?
|
Cognition | 2 | 2019 | 512 | 0.170 |
Why?
|
Fractures, Bone | 2 | 2020 | 142 | 0.160 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 441 | 0.160 |
Why?
|
Cardiovascular Diseases | 3 | 2020 | 1059 | 0.160 |
Why?
|
Rural Health | 3 | 2007 | 43 | 0.160 |
Why?
|
Emergency Service, Hospital | 4 | 2016 | 419 | 0.160 |
Why?
|
Incidence | 5 | 2020 | 1087 | 0.160 |
Why?
|
Multivariate Analysis | 6 | 2018 | 631 | 0.160 |
Why?
|
Metabolic Diseases | 1 | 2017 | 17 | 0.150 |
Why?
|
Anti-Inflammatory Agents | 2 | 2003 | 89 | 0.150 |
Why?
|
Sex Factors | 5 | 2016 | 619 | 0.150 |
Why?
|
Depressive Disorder | 2 | 2010 | 68 | 0.150 |
Why?
|
Interviews as Topic | 8 | 2008 | 240 | 0.150 |
Why?
|
Erythropoiesis | 1 | 2016 | 5 | 0.150 |
Why?
|
Attitude to Health | 2 | 2017 | 139 | 0.150 |
Why?
|
Dermatomyositis | 2 | 2007 | 19 | 0.150 |
Why?
|
Severity of Illness Index | 5 | 2019 | 846 | 0.150 |
Why?
|
Erythrocytes | 1 | 2016 | 42 | 0.150 |
Why?
|
Caffeine | 1 | 2016 | 31 | 0.150 |
Why?
|
Heart Rate | 2 | 2016 | 325 | 0.150 |
Why?
|
Genetic Loci | 3 | 2012 | 162 | 0.140 |
Why?
|
RNA-Binding Proteins | 1 | 2016 | 69 | 0.140 |
Why?
|
Age Distribution | 2 | 2014 | 197 | 0.140 |
Why?
|
Memory Disorders | 1 | 2016 | 57 | 0.140 |
Why?
|
Smoking Cessation | 1 | 2017 | 84 | 0.140 |
Why?
|
Melanoma | 2 | 2001 | 137 | 0.140 |
Why?
|
Polysomnography | 1 | 2016 | 31 | 0.140 |
Why?
|
Pair Bond | 1 | 2015 | 2 | 0.140 |
Why?
|
Animals, Laboratory | 1 | 2015 | 4 | 0.140 |
Why?
|
Housing, Animal | 1 | 2015 | 8 | 0.140 |
Why?
|
Tennessee | 6 | 2013 | 97 | 0.140 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2016 | 46 | 0.140 |
Why?
|
Infant, Premature, Diseases | 2 | 2012 | 22 | 0.140 |
Why?
|
Automobile Driving | 1 | 2015 | 19 | 0.140 |
Why?
|
Immunization Programs | 2 | 2013 | 25 | 0.140 |
Why?
|
Sleep | 1 | 2016 | 75 | 0.140 |
Why?
|
Alzheimer Disease | 1 | 2019 | 291 | 0.140 |
Why?
|
Case-Control Studies | 2 | 2016 | 886 | 0.130 |
Why?
|
Health Surveys | 5 | 2016 | 189 | 0.130 |
Why?
|
Clinical Medicine | 1 | 2015 | 12 | 0.130 |
Why?
|
Patient Dropouts | 1 | 2015 | 23 | 0.130 |
Why?
|
Child Welfare | 2 | 2006 | 19 | 0.130 |
Why?
|
Skin Neoplasms | 2 | 2001 | 205 | 0.130 |
Why?
|
Infant, Premature | 4 | 2016 | 63 | 0.130 |
Why?
|
Retrospective Studies | 8 | 2018 | 2930 | 0.130 |
Why?
|
Mutant Chimeric Proteins | 1 | 2014 | 6 | 0.130 |
Why?
|
HLA-B27 Antigen | 1 | 2014 | 8 | 0.130 |
Why?
|
HMGA2 Protein | 1 | 2014 | 14 | 0.130 |
Why?
|
KCNQ1 Potassium Channel | 1 | 2014 | 11 | 0.130 |
Why?
|
Heart Failure | 1 | 2000 | 574 | 0.130 |
Why?
|
Follow-Up Studies | 5 | 2019 | 2027 | 0.120 |
Why?
|
Homeostasis | 1 | 2014 | 140 | 0.120 |
Why?
|
Decision Support Techniques | 1 | 2015 | 103 | 0.120 |
Why?
|
Molecular Epidemiology | 2 | 2011 | 20 | 0.120 |
Why?
|
Models, Theoretical | 1 | 2015 | 119 | 0.120 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2013 | 28 | 0.120 |
Why?
|
Databases, Genetic | 1 | 2013 | 36 | 0.120 |
Why?
|
Pharmacogenetics | 1 | 2013 | 35 | 0.120 |
Why?
|
Dermatitis, Occupational | 1 | 2003 | 10 | 0.120 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2008 | 317 | 0.120 |
Why?
|
Organometallic Compounds | 1 | 2003 | 18 | 0.120 |
Why?
|
Pharmaceutical Preparations | 1 | 2013 | 29 | 0.120 |
Why?
|
Patient Compliance | 1 | 2015 | 191 | 0.120 |
Why?
|
Women's Health Services | 1 | 2013 | 9 | 0.120 |
Why?
|
Pyridines | 1 | 2003 | 69 | 0.120 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2003 | 26 | 0.120 |
Why?
|
Clobetasol | 1 | 2003 | 25 | 0.120 |
Why?
|
Zinc | 1 | 2003 | 31 | 0.120 |
Why?
|
Dermatology | 2 | 2002 | 153 | 0.110 |
Why?
|
Lipectomy | 1 | 2002 | 9 | 0.110 |
Why?
|
Antiviral Agents | 1 | 2013 | 100 | 0.110 |
Why?
|
Patient Acceptance of Health Care | 2 | 2005 | 154 | 0.110 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2002 | 27 | 0.110 |
Why?
|
Whooping Cough | 1 | 2012 | 8 | 0.110 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2012 | 5 | 0.110 |
Why?
|
Liver Diseases | 3 | 2008 | 61 | 0.110 |
Why?
|
Odds Ratio | 4 | 2019 | 457 | 0.110 |
Why?
|
Platelet Count | 1 | 2012 | 20 | 0.110 |
Why?
|
Dermatologic Agents | 2 | 2002 | 208 | 0.110 |
Why?
|
Mood Disorders | 1 | 2012 | 19 | 0.110 |
Why?
|
Rotavirus Vaccines | 1 | 2012 | 6 | 0.110 |
Why?
|
Rotavirus Infections | 1 | 2012 | 10 | 0.110 |
Why?
|
Blood Platelets | 1 | 2012 | 37 | 0.110 |
Why?
|
Asian Continental Ancestry Group | 5 | 2012 | 114 | 0.110 |
Why?
|
Estrogens | 1 | 2013 | 170 | 0.110 |
Why?
|
Alcoholism | 1 | 2012 | 61 | 0.100 |
Why?
|
Mental Disorders | 1 | 2012 | 96 | 0.100 |
Why?
|
Postmenopause | 3 | 2020 | 398 | 0.100 |
Why?
|
Time Factors | 5 | 2016 | 1874 | 0.100 |
Why?
|
Memory | 1 | 2013 | 175 | 0.100 |
Why?
|
Leukocyte Count | 1 | 2011 | 54 | 0.100 |
Why?
|
Family | 2 | 2010 | 120 | 0.100 |
Why?
|
Phototherapy | 1 | 2001 | 47 | 0.100 |
Why?
|
Immunity, Maternally-Acquired | 1 | 2011 | 2 | 0.100 |
Why?
|
Body Mass Index | 6 | 2016 | 890 | 0.100 |
Why?
|
Adiposity | 1 | 2012 | 208 | 0.100 |
Why?
|
Lod Score | 4 | 2007 | 86 | 0.100 |
Why?
|
Respiratory Syncytial Virus Infections | 1 | 2000 | 9 | 0.100 |
Why?
|
Body Composition | 3 | 2017 | 365 | 0.100 |
Why?
|
Creatinine | 2 | 2008 | 183 | 0.100 |
Why?
|
Longitudinal Studies | 3 | 2019 | 694 | 0.100 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2011 | 27 | 0.100 |
Why?
|
Intention to Treat Analysis | 2 | 2020 | 22 | 0.100 |
Why?
|
Quality of Health Care | 1 | 2001 | 134 | 0.100 |
Why?
|
Hemoglobin C | 1 | 2010 | 2 | 0.100 |
Why?
|
Vaccination | 1 | 2011 | 118 | 0.100 |
Why?
|
Oceanic Ancestry Group | 2 | 2007 | 6 | 0.100 |
Why?
|
Sickle Cell Trait | 1 | 2010 | 13 | 0.090 |
Why?
|
Pneumococcal Infections | 1 | 2010 | 26 | 0.090 |
Why?
|
Patient Satisfaction | 1 | 2002 | 216 | 0.090 |
Why?
|
Family Health | 2 | 2007 | 86 | 0.090 |
Why?
|
Age Factors | 5 | 2007 | 1058 | 0.090 |
Why?
|
Mutation, Missense | 1 | 2010 | 50 | 0.090 |
Why?
|
Arteries | 1 | 2010 | 61 | 0.090 |
Why?
|
Ambulatory Care Facilities | 2 | 2020 | 62 | 0.090 |
Why?
|
Socioeconomic Factors | 4 | 2019 | 381 | 0.090 |
Why?
|
Chromosome Mapping | 3 | 2003 | 213 | 0.090 |
Why?
|
Gene Frequency | 5 | 2007 | 272 | 0.090 |
Why?
|
Treatment Outcome | 6 | 2010 | 2886 | 0.090 |
Why?
|
Antidepressive Agents | 2 | 2020 | 59 | 0.090 |
Why?
|
Ambulatory Care | 1 | 2000 | 96 | 0.090 |
Why?
|
Diet, Fat-Restricted | 1 | 2009 | 30 | 0.090 |
Why?
|
Anti-Bacterial Agents | 2 | 2000 | 283 | 0.090 |
Why?
|
Clinical Competence | 1 | 2001 | 296 | 0.090 |
Why?
|
Prognosis | 3 | 2017 | 1342 | 0.080 |
Why?
|
Medical History Taking | 1 | 2008 | 32 | 0.080 |
Why?
|
Apolipoproteins B | 1 | 2007 | 44 | 0.080 |
Why?
|
Autoimmunity | 1 | 2007 | 26 | 0.080 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2011 | 38 | 0.080 |
Why?
|
Regression Analysis | 3 | 2008 | 266 | 0.080 |
Why?
|
Genetic Markers | 3 | 2001 | 134 | 0.080 |
Why?
|
DNA | 1 | 2008 | 207 | 0.080 |
Why?
|
RNA Splice Sites | 1 | 2007 | 1 | 0.080 |
Why?
|
Gestational Age | 2 | 2002 | 92 | 0.080 |
Why?
|
Religion and Psychology | 1 | 2007 | 7 | 0.080 |
Why?
|
Preventive Medicine | 1 | 2007 | 6 | 0.080 |
Why?
|
Equipment and Supplies | 1 | 2007 | 12 | 0.080 |
Why?
|
Ownership | 1 | 2007 | 14 | 0.080 |
Why?
|
Cholesterol, LDL | 1 | 2007 | 165 | 0.080 |
Why?
|
Cation Transport Proteins | 1 | 2007 | 26 | 0.080 |
Why?
|
Cultural Diversity | 1 | 2007 | 17 | 0.070 |
Why?
|
Cholesterol | 2 | 2019 | 231 | 0.070 |
Why?
|
Fetal Organ Maturity | 2 | 2016 | 7 | 0.070 |
Why?
|
Movement Disorders | 2 | 2019 | 22 | 0.070 |
Why?
|
Asian Americans | 1 | 2007 | 99 | 0.070 |
Why?
|
California | 3 | 2012 | 61 | 0.070 |
Why?
|
Quantitative Trait Loci | 1 | 2007 | 154 | 0.070 |
Why?
|
Heterozygote | 2 | 2019 | 54 | 0.070 |
Why?
|
Patient Education as Topic | 2 | 2005 | 235 | 0.070 |
Why?
|
Double-Blind Method | 2 | 2003 | 480 | 0.070 |
Why?
|
Medicaid | 2 | 2000 | 82 | 0.070 |
Why?
|
Health Status Disparities | 1 | 2007 | 105 | 0.070 |
Why?
|
Health Promotion | 1 | 2008 | 212 | 0.070 |
Why?
|
Models, Statistical | 1 | 2006 | 157 | 0.070 |
Why?
|
Accidental Falls | 1 | 2006 | 77 | 0.070 |
Why?
|
Administration, Topical | 3 | 2003 | 129 | 0.070 |
Why?
|
Complementary Therapies | 1 | 2006 | 74 | 0.070 |
Why?
|
Energy Intake | 3 | 2000 | 122 | 0.070 |
Why?
|
Diabetic Foot | 1 | 2005 | 18 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 39 | 0.060 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 370 | 0.060 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2005 | 24 | 0.060 |
Why?
|
Specialization | 1 | 2005 | 30 | 0.060 |
Why?
|
Health Services for the Aged | 1 | 2005 | 25 | 0.060 |
Why?
|
Medicine | 1 | 2005 | 30 | 0.060 |
Why?
|
Rural Health Services | 1 | 2005 | 26 | 0.060 |
Why?
|
Linkage Disequilibrium | 2 | 2016 | 222 | 0.060 |
Why?
|
Catheterization, Central Venous | 1 | 2005 | 60 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2016 | 706 | 0.060 |
Why?
|
Environmental Monitoring | 1 | 2004 | 26 | 0.060 |
Why?
|
Nerve Tissue Proteins | 2 | 2016 | 95 | 0.060 |
Why?
|
Acute Disease | 2 | 2018 | 234 | 0.060 |
Why?
|
Administration, Inhalation | 2 | 2000 | 84 | 0.060 |
Why?
|
Medicare | 1 | 2005 | 181 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2011 | 521 | 0.060 |
Why?
|
Outpatient Clinics, Hospital | 2 | 2013 | 13 | 0.060 |
Why?
|
Seasons | 2 | 2013 | 81 | 0.060 |
Why?
|
Communication | 1 | 2004 | 121 | 0.060 |
Why?
|
Alleles | 2 | 2016 | 273 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2005 | 226 | 0.050 |
Why?
|
Immunization Schedule | 2 | 2012 | 21 | 0.050 |
Why?
|
Dysplastic Nevus Syndrome | 1 | 1992 | 3 | 0.050 |
Why?
|
Recombination, Genetic | 1 | 1992 | 19 | 0.050 |
Why?
|
Risk Assessment | 2 | 2006 | 1285 | 0.050 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 1992 | 7 | 0.050 |
Why?
|
Animals | 3 | 2016 | 6402 | 0.050 |
Why?
|
Lasers | 2 | 2002 | 17 | 0.050 |
Why?
|
Genomics | 1 | 2022 | 78 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 398 | 0.050 |
Why?
|
Receptors, Cell Surface | 2 | 2012 | 71 | 0.050 |
Why?
|
Virginia | 3 | 2008 | 64 | 0.050 |
Why?
|
Genetic Heterogeneity | 1 | 2001 | 14 | 0.050 |
Why?
|
Africa | 2 | 2016 | 24 | 0.050 |
Why?
|
Demography | 2 | 2015 | 109 | 0.050 |
Why?
|
Europe | 2 | 2016 | 82 | 0.050 |
Why?
|
Research Design | 1 | 2003 | 271 | 0.050 |
Why?
|
Lactates | 1 | 1990 | 2 | 0.050 |
Why?
|
Retinol-Binding Proteins, Plasma | 1 | 2000 | 4 | 0.050 |
Why?
|
Retinol-Binding Proteins | 1 | 2000 | 3 | 0.050 |
Why?
|
Parents | 2 | 2012 | 115 | 0.050 |
Why?
|
Gallbladder Diseases | 1 | 2020 | 5 | 0.050 |
Why?
|
Dietary Carbohydrates | 1 | 1990 | 21 | 0.050 |
Why?
|
Allergens | 1 | 2000 | 16 | 0.050 |
Why?
|
Patient Preference | 1 | 2020 | 37 | 0.050 |
Why?
|
Drug Utilization Review | 1 | 2000 | 17 | 0.050 |
Why?
|
Echocardiography, Doppler | 1 | 2000 | 39 | 0.050 |
Why?
|
Cross-Over Studies | 1 | 2000 | 90 | 0.050 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2000 | 67 | 0.050 |
Why?
|
Bronchoscopy | 1 | 2000 | 56 | 0.050 |
Why?
|
Data Collection | 2 | 2008 | 158 | 0.050 |
Why?
|
Medroxyprogesterone Acetate | 1 | 2020 | 89 | 0.050 |
Why?
|
Anemia, Sickle Cell | 1 | 2000 | 40 | 0.050 |
Why?
|
Leptin | 1 | 2000 | 66 | 0.050 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2020 | 125 | 0.050 |
Why?
|
Anti-Asthmatic Agents | 1 | 2000 | 71 | 0.050 |
Why?
|
Referral and Consultation | 1 | 2020 | 106 | 0.050 |
Why?
|
Freezing | 1 | 1999 | 2 | 0.050 |
Why?
|
Centrifugation | 1 | 1999 | 3 | 0.050 |
Why?
|
Analysis of Variance | 2 | 2016 | 390 | 0.050 |
Why?
|
Nutritive Value | 1 | 1999 | 7 | 0.050 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2019 | 7 | 0.040 |
Why?
|
Catechol O-Methyltransferase | 1 | 2019 | 13 | 0.040 |
Why?
|
Recombinases | 1 | 2019 | 2 | 0.040 |
Why?
|
Membrane Transport Proteins | 1 | 2019 | 24 | 0.040 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2019 | 29 | 0.040 |
Why?
|
Alternative Splicing | 1 | 2019 | 27 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2000 | 139 | 0.040 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2019 | 73 | 0.040 |
Why?
|
Apolipoproteins E | 1 | 2019 | 101 | 0.040 |
Why?
|
Lung | 1 | 2000 | 232 | 0.040 |
Why?
|
Atrial Natriuretic Factor | 1 | 1988 | 12 | 0.040 |
Why?
|
Canada | 2 | 2008 | 43 | 0.040 |
Why?
|
Ascites | 1 | 1988 | 13 | 0.040 |
Why?
|
Insulin | 1 | 1990 | 364 | 0.040 |
Why?
|
North America | 2 | 2009 | 33 | 0.040 |
Why?
|
Lipids | 1 | 1999 | 215 | 0.040 |
Why?
|
Liver Cirrhosis | 1 | 1988 | 75 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2017 | 29 | 0.040 |
Why?
|
Pedigree | 2 | 2012 | 149 | 0.040 |
Why?
|
Far East | 1 | 2016 | 4 | 0.040 |
Why?
|
Zebrafish | 1 | 2016 | 25 | 0.040 |
Why?
|
Safety | 2 | 2008 | 70 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2016 | 59 | 0.040 |
Why?
|
Sex Distribution | 2 | 2008 | 187 | 0.040 |
Why?
|
Arthritis | 2 | 2008 | 37 | 0.040 |
Why?
|
Snoring | 1 | 2016 | 7 | 0.040 |
Why?
|
Autonomic Nervous System | 1 | 2016 | 42 | 0.040 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 10 | 0.040 |
Why?
|
Cerebellum | 1 | 2016 | 25 | 0.040 |
Why?
|
Life Change Events | 1 | 2016 | 21 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2017 | 236 | 0.040 |
Why?
|
Twins | 1 | 1986 | 2 | 0.040 |
Why?
|
Atrophy | 1 | 2016 | 51 | 0.040 |
Why?
|
Linear Models | 1 | 2017 | 421 | 0.040 |
Why?
|
Oximetry | 1 | 2016 | 28 | 0.040 |
Why?
|
Body Height | 1 | 1986 | 31 | 0.030 |
Why?
|
Heart Diseases | 2 | 2008 | 101 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2016 | 71 | 0.030 |
Why?
|
Proxy | 1 | 2015 | 9 | 0.030 |
Why?
|
Frail Elderly | 1 | 2016 | 60 | 0.030 |
Why?
|
Psychological Tests | 1 | 2015 | 32 | 0.030 |
Why?
|
Renin | 1 | 2016 | 153 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2014 | 467 | 0.030 |
Why?
|
Term Birth | 1 | 2015 | 3 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2016 | 116 | 0.030 |
Why?
|
Macaca mulatta | 1 | 2015 | 133 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2016 | 247 | 0.030 |
Why?
|
Systole | 1 | 2015 | 90 | 0.030 |
Why?
|
Cross-Cultural Comparison | 2 | 2005 | 24 | 0.030 |
Why?
|
Disease Outbreaks | 1 | 2015 | 34 | 0.030 |
Why?
|
Health Status Indicators | 1 | 2015 | 68 | 0.030 |
Why?
|
Genome | 1 | 2014 | 43 | 0.030 |
Why?
|
Influenza B virus | 1 | 2014 | 15 | 0.030 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2014 | 17 | 0.030 |
Why?
|
Aldosterone | 1 | 2014 | 34 | 0.030 |
Why?
|
Angiotensin II | 1 | 2016 | 359 | 0.030 |
Why?
|
Computer Simulation | 1 | 2015 | 187 | 0.030 |
Why?
|
Angiotensin I | 1 | 2016 | 326 | 0.030 |
Why?
|
Life Style | 1 | 2016 | 372 | 0.030 |
Why?
|
Mexico | 1 | 2003 | 63 | 0.030 |
Why?
|
Databases, Factual | 1 | 2014 | 320 | 0.030 |
Why?
|
Genetics, Population | 1 | 2003 | 30 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 169 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2003 | 29 | 0.030 |
Why?
|
New York | 1 | 2013 | 18 | 0.030 |
Why?
|
Hyaline Membrane Disease | 1 | 2002 | 1 | 0.030 |
Why?
|
Apgar Score | 1 | 2002 | 5 | 0.030 |
Why?
|
Skin Absorption | 1 | 2002 | 9 | 0.030 |
Why?
|
Utilization Review | 1 | 2013 | 16 | 0.030 |
Why?
|
Intensive Care, Neonatal | 1 | 2002 | 7 | 0.030 |
Why?
|
Solutions | 1 | 2002 | 25 | 0.030 |
Why?
|
Surgicenters | 1 | 2002 | 3 | 0.030 |
Why?
|
Physicians' Offices | 1 | 2002 | 9 | 0.030 |
Why?
|
Ohio | 1 | 2013 | 54 | 0.030 |
Why?
|
Infant Mortality | 1 | 2002 | 11 | 0.030 |
Why?
|
Models, Genetic | 2 | 2007 | 102 | 0.030 |
Why?
|
Developmental Disabilities | 1 | 2012 | 12 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2016 | 480 | 0.030 |
Why?
|
New York City | 1 | 2002 | 13 | 0.030 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2012 | 3 | 0.030 |
Why?
|
Postoperative Period | 1 | 2002 | 89 | 0.030 |
Why?
|
Chromosomes, Human, Pair 10 | 1 | 2012 | 10 | 0.030 |
Why?
|
Maryland | 1 | 2002 | 26 | 0.030 |
Why?
|
Serine Endopeptidases | 1 | 2012 | 20 | 0.030 |
Why?
|
Precipitating Factors | 1 | 2012 | 2 | 0.030 |
Why?
|
Focus Groups | 1 | 2002 | 97 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 279 | 0.030 |
Why?
|
Receptors, Nicotinic | 1 | 2012 | 15 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 236 | 0.030 |
Why?
|
Postpartum Period | 1 | 2012 | 28 | 0.030 |
Why?
|
Pennsylvania | 1 | 2002 | 77 | 0.030 |
Why?
|
Proteoglycans | 1 | 2012 | 30 | 0.030 |
Why?
|
Gastroenteritis | 1 | 2012 | 10 | 0.030 |
Why?
|
Platelet Aggregation | 1 | 2012 | 21 | 0.030 |
Why?
|
Radiation Dosage | 1 | 2002 | 65 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2012 | 99 | 0.030 |
Why?
|
Hot Temperature | 1 | 2012 | 62 | 0.030 |
Why?
|
Databases as Topic | 1 | 2001 | 24 | 0.030 |
Why?
|
Cyclosporine | 1 | 2001 | 33 | 0.030 |
Why?
|
Meta-Analysis as Topic | 1 | 2001 | 42 | 0.030 |
Why?
|
Antirheumatic Agents | 1 | 2001 | 27 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2002 | 265 | 0.030 |
Why?
|
Arthritis, Rheumatoid | 1 | 2001 | 31 | 0.030 |
Why?
|
Program Evaluation | 1 | 2012 | 166 | 0.030 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2011 | 11 | 0.030 |
Why?
|
Duffy Blood-Group System | 1 | 2011 | 4 | 0.030 |
Why?
|
Chemokine CXCL2 | 1 | 2011 | 9 | 0.030 |
Why?
|
Predictive Value of Tests | 2 | 2005 | 774 | 0.030 |
Why?
|
DNA Replication | 1 | 2011 | 23 | 0.030 |
Why?
|
Artifacts | 1 | 2011 | 34 | 0.030 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2011 | 6 | 0.030 |
Why?
|
Microfilament Proteins | 1 | 2011 | 34 | 0.030 |
Why?
|
Recurrence | 1 | 2002 | 210 | 0.030 |
Why?
|
Heart Defects, Congenital | 1 | 2000 | 28 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2016 | 1144 | 0.020 |
Why?
|
Cardiac Output, Low | 1 | 2000 | 10 | 0.020 |
Why?
|
Pulsatile Flow | 1 | 2010 | 24 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2012 | 198 | 0.020 |
Why?
|
Myocarditis | 1 | 2000 | 6 | 0.020 |
Why?
|
Elasticity | 1 | 2010 | 33 | 0.020 |
Why?
|
Risk | 1 | 2011 | 290 | 0.020 |
Why?
|
Streptococcus pneumoniae | 1 | 2010 | 36 | 0.020 |
Why?
|
Arm | 1 | 2010 | 29 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2001 | 194 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2010 | 59 | 0.020 |
Why?
|
Leg | 1 | 2010 | 54 | 0.020 |
Why?
|
Brachial Artery | 1 | 2010 | 65 | 0.020 |
Why?
|
Infant, Low Birth Weight | 1 | 2008 | 9 | 0.020 |
Why?
|
Nutritional Sciences | 1 | 2008 | 8 | 0.020 |
Why?
|
Kentucky | 1 | 2007 | 15 | 0.020 |
Why?
|
Body Weights and Measures | 1 | 2007 | 23 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2007 | 39 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 369 | 0.020 |
Why?
|
Hemosiderosis | 1 | 2007 | 2 | 0.020 |
Why?
|
Protestantism | 1 | 2007 | 5 | 0.020 |
Why?
|
Vietnam | 1 | 2007 | 23 | 0.020 |
Why?
|
Point Mutation | 1 | 2007 | 23 | 0.020 |
Why?
|
Health Education | 1 | 2008 | 119 | 0.020 |
Why?
|
Laundering | 1 | 2006 | 4 | 0.020 |
Why?
|
Baths | 1 | 2006 | 6 | 0.020 |
Why?
|
Up-Regulation | 1 | 2007 | 180 | 0.020 |
Why?
|
Attitude | 1 | 2006 | 35 | 0.020 |
Why?
|
Religion | 1 | 2006 | 30 | 0.020 |
Why?
|
Family Characteristics | 1 | 2006 | 30 | 0.020 |
Why?
|
Dermatitis | 1 | 2005 | 19 | 0.020 |
Why?
|
Comorbidity | 1 | 2007 | 531 | 0.020 |
Why?
|
Adaptation, Psychological | 1 | 2007 | 124 | 0.020 |
Why?
|
Pruritus | 1 | 2005 | 40 | 0.020 |
Why?
|
Confidentiality | 1 | 2005 | 21 | 0.020 |
Why?
|
Social Support | 1 | 2007 | 162 | 0.020 |
Why?
|
Risk-Taking | 1 | 2006 | 88 | 0.020 |
Why?
|
American Native Continental Ancestry Group | 1 | 2005 | 13 | 0.020 |
Why?
|
Geography | 1 | 2005 | 29 | 0.020 |
Why?
|
Thrombosis | 1 | 2005 | 58 | 0.020 |
Why?
|
Educational Status | 1 | 2005 | 162 | 0.020 |
Why?
|
Poverty | 1 | 2005 | 98 | 0.020 |
Why?
|
Communication Barriers | 1 | 2004 | 20 | 0.020 |
Why?
|
Language | 1 | 2004 | 43 | 0.020 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2003 | 9 | 0.020 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2003 | 15 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2005 | 177 | 0.010 |
Why?
|
Genetic Counseling | 1 | 2003 | 7 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1992 | 36 | 0.010 |
Why?
|
Chromosomes, Human | 1 | 2001 | 9 | 0.010 |
Why?
|
Matched-Pair Analysis | 1 | 2001 | 10 | 0.010 |
Why?
|
Nuclear Family | 1 | 2001 | 16 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 1992 | 95 | 0.010 |
Why?
|
Patient Selection | 1 | 2003 | 249 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2001 | 340 | 0.010 |
Why?
|
Theophylline | 1 | 2000 | 4 | 0.010 |
Why?
|
Lactic Acid | 1 | 1990 | 50 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 1990 | 134 | 0.010 |
Why?
|
Basal Metabolism | 1 | 2000 | 8 | 0.010 |
Why?
|
Health Resources | 1 | 2000 | 32 | 0.010 |
Why?
|
Adrenergic beta-Agonists | 1 | 2000 | 48 | 0.010 |
Why?
|
Administration, Oral | 1 | 2000 | 163 | 0.010 |
Why?
|
Fasting | 1 | 2000 | 98 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2000 | 110 | 0.010 |
Why?
|
Bronchodilator Agents | 1 | 2000 | 82 | 0.010 |
Why?
|
Sex Characteristics | 1 | 2000 | 158 | 0.010 |
Why?
|
Chronic Disease | 1 | 2000 | 359 | 0.010 |
Why?
|
Radioimmunoassay | 1 | 1988 | 21 | 0.010 |
Why?
|
Diet | 1 | 2000 | 346 | 0.010 |
Why?
|